Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.
Under the terms of the agreement the costs of the clinical trial will be shared equally by Quest and Hemispherx. In addition, Hemispherx will provide appropriate technical expertise and relevant data to support the regulatory process necessary to conduct the clinical trial. Hemispherx has also agreed to store and maintain clinical supply inventory of Oregovomab at their state of the art manufacturing facility in New Brunswick.
"This collaborative clinical study is indicative of our progression as a cancer immunotherapy company and we look forward to working with Hemispherx in the conduct of this important clinical trial to evaluate the utility of our product in combination with Ampligen", said Dr. Madi R. Madiyalakan, Quest's Chief Executive Officer. The Company is in negotiation with various investigators in Canada and the U.S. to initiate this clinical study in the coming months.